KIDNEY INJURY IN CANCER THERAPY
https://doi.org/10.24884/1561-6274-2018-22-5-17-24
Abstract
Кidney injury is a frequent and significant complication of cancer and cancer therapy. The kidneys are susceptible to injury from malignant infiltration, damage by metabolites of malignant cells, glomerular injury, nephrotoxic drugs including chemotherapeutic agents. Also bone marrow transplantation complications, infections with immune suppression (including septicemia), tumor lysis syndrome should be taken into account. Chemotherapeutic agents are a common cause of acute kidney injury but can potentially lead to chronic kidney disease development in cancer patients. This article summarizes risk factors of acute kidney injury in cancer patients. Risk factors are divided into two groups. The systemic are decrease of total circulating blood volume, infiltration of kidney tissue by tumor cells, dysproteinemia, electrolyte disturbances. The local (renal) risk factors are microcirculation disturbances, drugs biotransformation with formation of reactive oxygen intermediates, high concentration of nephrotoxic agents in proximal tubules and its sensitivity to ischemia. Drug-related risk factors include: drugs combination with cytotoxic effect high doses long term use necessity, direct cytotoxic effect of not only chemotherapeutic agents but also its metabolites, mean solubility forming intratubular precipitates. Early diagnosis, timely prevention and treatment of these complications provide significantly improve nononcologic results of treatment.
About the Authors
E. V. Burnasheva
Rostov State Medical University
Russian Federation
Russian Federation
Hematology department
344022, Russia, Rostov-on-Don, Nakhichevansky 29
MD, PhD, assistant
Phone: + 7 863-201-44-25, + 7 918-557-63-18
Y. V. Shatokhin
Rostov State Medical University
Russian Federation
Russian Federation
Hematology department
344022, Russia, Rostov-on-Don, Nakhichevansky 29
Prof. Yuri V. Shatokhin, MD, PhD, DMed Sci, Head of the departmentr
Phone: + 7 863-263-23-41, mobile +7 928-100-75-43
I. V. Snezhko
Rostov State Medical University
Russian Federation
Russian Federation
Hematology department
344022, Russia, Rostov-on-Don, Nakhichevansky 29
Associate professor Irina V. Snezhko, MD. PhD
Phone: +7 863-263-23-41, +7 928-605-96-61
A. A. Matsuga
Rostov State Medical University
City hospital №7
Russian Federation
Russian Federation
Hematology department, assistant
Hematology unit, head of hematological unit
344022, Russia, Rostov-on-Don, Nakhichevansky 29
344004, Russia, Rostov-on-Don ul. Profsoyuznaya 49/52
MD
Phone: + 7 863-263-23-41, +7 918-520-46-25
References
1. Givens ML, Wethern J. Renal Complications in Oncologic Patients. Emerg Med Clin North Am 2009;27: 283-291. doi:10.1016/j.emc.2009.01.001
2. Wilson FP, Berns JS. Tumor Lysis Syndrome: New Challenges and Recent Advances. Adv Chronic Kidney Dis 2014;21(1):16-26. doi: 10.1053/j.ackd.2013.07.001
3. Luciano RL, Brewster UC. Kidney Involvement in Leukemia and Lymphoma. Adv Chronic Kidney Dis 2014;21(1):27-35. doi: 10.1053/j.ackd.2013.07.004
4. Jhaveri KD, Shah HH, Patel C et al. Glomerular Diseases Associated With Cancer, Chemotherapy, and Hematopoietic Stem Cell Transplantation. Adv Chronic Kidney Dis 2014;21(1): 48-55. doi: 10.1053/j.ackd.2013.08.003
5. Perazella MA, Berns JS, Rosner MH. Cancer and the Kidney: The Growth of Onco- nephrology. Adv Chronic Kidney Dis 2014;21(1):4-6. doi: 10.1053/j.ackd.2013.09.002
6. Корман ДБ. Основы противоопухолевой химиотерапии. Практическая медицина, М., 2006: 518; [Korman DB. Fundamentals of antitumor chemotherapy. Practical medicine, M., 2006: 518]
7. Shirali AC, Perazella MA. Tubulointerstitial Injury Associated With Chemotherapeutic Agents. Adv Chronic Kidney Dis 2014; 21(1):56-63. doi: 10.1053/j.ackd.2013.06.010
8. Akilesh S, Juaire N, Duffield JS. et al Chronic Ifosfamide Toxicity: Kidney Pathology and Pathophysiology. Am J Kidney Dis 2014; 63(5):843-850. doi: 10.1053/j.ajkd.2013.11.028
9. Campbell GA, Hu D, Okusa MD. Acute Kidney Injury in the Cancer Patient. Adv Chronic Kidney Dis 2014;21(1):64-71. doi: 10.1053/j.ackd.2013.08.002
10. Lameire N. Nephrotoxicity of recent anti-cancer agents. Clin Kidney J 2014;7:11-12. doi: 10.1093/ckj/sft135
11. Zupancic M, Shah PC, Shah-Khan F. Gemcitabineassociated thrombotic thrombocytopenic purpura. Lancet Oncol 2007; 8:634-641. doi: 10.1038/cddis.2017.552
12. Волкова МА. Клиническая онкогематология. Медицина, М., 2007: 1120 [Volkova MA. Clinical oncohematology. Medicine, M., 2007: 1120]
13. Ahn MJ, D’Cruz A, Vermorken JB et al. Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. Oral Oncol 2016;53:10-16. doi: 10.1016/j.oraloncology.2015.11.019
14. Martinez-Castelao A, Gorriz JL, Bover J et al. Consensus document for the detection and management of chronic kidney disease. Nefrologia 2014;34(2):243-262. doi: 10.3265/Nefrologia.pre2014.Feb.12455
15. Aapro M, Launay-Vacher V. Importance of monitoring renal function in patients with cancer. Cancer Treat Rev 2012;38:235-240. doi: 10.1016/j.ctrv.2011.05.001
16. Finkel M, Goldstein A, Steinberg Y et al. Cisplatinum nephrotoxicity in oncology therapeutics: retrospective review of patients treated between 2005 and 2012. Pediatr Nephrol 2014;29:2421–2424. doi: 10.1007/s00467-014-2935-z
17. Damiano S, Ciarcia R, Montagnaro S et al. Prevention of Nephrotoxicity Induced by Cyclosporine-A: Role of Antioxidants. J Cell Biochem 2015;116:364-369. doi: 10.1002/jcb.25022
18. M a T, Huang C, Xu Q et al. Suppression of BMP-7 by histone deacetylase 2 promoted apoptosis of renal tubular epithelial cells in acute kidney injury. Cell Death Dis 2017;8(10):31-39
19. Kumar P, Barua CC, Sulakhiya K et al. Curcumin Ameliorates Cisplatin-Induced Nephrotoxicity and Potentiates Its Anticancer Activity in SD Rats: Potential Role of Curcumin in Breast Cancer Chemotherapy. Front Pharmacol 2017;8:1-32
20. A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy. ClinicalTrials. gov Identifier: NCT03480971 First Posted: March 29, 2018
21. Skinner R, Kaplan R, Nathan PC. Renal and Pulmonary Late Effects of Cancer Therapy. Semin Oncol 2013;40(6):757-773. doi: 10.1053/j.seminoncol.2013.09.009
22. Lichtmana SM, Wildiersb H, Launay-Vacherc V et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007;43:14-34. doi: 10.1016/j.ejca.2006.11.004
Review
For citations:
Burnasheva E.V., Shatokhin Y.V., Snezhko I.V., Matsuga A.A. KIDNEY INJURY IN CANCER THERAPY. Nephrology (Saint-Petersburg). 2018;22(5):17-24. (In Russ.) https://doi.org/10.24884/1561-6274-2018-22-5-17-24
Views:
39762
Email this article 